Therapeutics: MAP kinase kinase kinase 14 (MAP3K14; NIK); tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3)

In vitro, mouse and patient sample studies suggest inhibiting MAP3K14 could help treat diffuse large B cell lymphoma (DLBCL). Of 119 DLBCL patient samples, 15% had inactivating mutations in TRAF3, a n...